Pacific Bio (PACB) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Piper Jaffray Downgrades Pacific Biosciences of California (PACB) to Neutral
February 4, 2016 6:37 AM ESTPiper Jaffray downgraded Pacific Biosciences of California (NASDAQ: PACB) from Overweight to Neutral with a price target of $11.00 (from $9.00).
Analyst William Quirk commented, "PacBio reported 4Q15 revenue of $36.3M, ~in line with the Street's $36.6M forecast. EPS of $(0.02) was also in line. PacBio... More
